Technology Prognosis: Luxturna (Voretigene Neparvovec-rzyl)
Proposed Use Gene therapy for treatment of vision loss due to RPE65 gene mutation
Regulatory Status Phase I/II Trials Complete Phase III Trials in Progress Phase III Trials Published FDA Filing Complete FDA Approved
Estimated Commercial Availability Unable to Determine >2 years 1 to 2 years <6 months Currently Available

Check out this technology prognosis to learn more.